Can vaginal estrogen be safe for breast cancer survivors? new study investigates

NCT ID NCT00984399

Completed Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a low-dose vaginal estrogen tablet (Vagifem) is safe for women who have had breast cancer and are taking aromatase inhibitors. 31 postmenopausal women with a history of breast cancer used the tablet for vaginal dryness. Researchers measured their blood estrogen levels to see if the estrogen gets absorbed into the bloodstream, which could potentially raise cancer risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATROPHIC VAGINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm postmenopausal atrophic vaginitis vaginitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATROPHIC VAGINITIS BREAST CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Suffolk

Commack, New York, 11725, United States
Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital

Sleepy Hollow, New York, United States
Memorial Sloan Kettering at Mercy Medical Center

Rockville Centre, New York, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.